释 义 n. 埃罗替尼；厄洛替尼；特罗凯
例 句 By inhibition of phosphorylation of tyrosine kinase, erlotinib blocks the EGFR tyrosine kinase protein in the cancer cell from getting a message that tells the cell to grow and divide. 盐酸埃罗替尼是一种小分子表皮生长因子酪氨酸激酶可逆抑制剂，通过抑制酪氨酸激酶的磷酸化，阻断信号传导，抑制肿瘤生长。
Ramuciromab联合厄洛替尼治疗未经治疗、EGFR突变的晚期非小细胞肺癌 (RELAY): 一项随机、双盲、安慰剂对照、3期临床试验
作者： Kazuhiko Nakagawa
Between Jan 28, 2016, and Feb 1, 2018, 449 eligible patients were enrolled and randomly assigned to treatment with ramucirumab plus erlotinib (n=224) or placebo plus erlotinib (n=225). Median duration of follow-up was 20.7 months (IQR 15.8-27.2). At the time of primary analysis, progression-free survival was significantly longer in the ramucirumab plus erlotinib group (19.4 months [95% CI 15.4-21.6]) than in the placebo plus erlotinib group (12.4 months [11.0-13.5]), with a stratified hazard ratio of 0.59 (95% CI 0.46-0.76; p<0.0001). Grade 3-4 treatment-emergent adverse events were reported in 159 (72%) of 221 patients in the ramucirumab plus erlotinib group versus 121 (54%) of 225 in the placebo plus erlotinib group. The most common grade 3-4 treatment-emergent adverse events in the ramucirumab plus erlotinib group were hypertension (52 [24%]; grade 3 only) and dermatitis acneiform (33 [15%]), and in the placebo plus erlotinib group were dermatitis acneiform (20 [9%]) and increased alanine aminotransferase (17 [8%]).